OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals
News Nov 15, 2005
OSI acquired Eyetech for approximately $685 million in cash and approximately 5.7 million shares of OSI's common stock.
Net of Eyetech's cash and net operating loss carryforwards, OSI valued the acquisition at approximately $650 million.
Eyetech stockholders will receive $15 per share in cash and 0.12275 of OSI shares for each share of Eyetech owned as of the closing date.
The transaction creates a company that focuses on three therapeutic disease areas of significant market potential: oncology, eye diseases and diabetes, and effectively leverages the Company's core expertise in drug discovery and development.
The Company now has two major marketed products (for the treatment of cancer and age-related macular degeneration) and a product pipeline offering both indications for the marketed products and therapeutics in all three disease areas.
Tarceva® and Macugen® are two of the exciting biotech products launched in recent years.
Tarceva, OSI's flagship product, is approved in the United States for the treatment of advanced non-small cell lung cancer (NSCLC) and pancreatic cancer and approved in the European Union for advanced NSCLC.
Macugen is approved in the United States for the treatment of neovascular age-related macular degeneration and European approval is anticipated by year end.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE